QNTM

FRPT

Consumer Staplesmid cap
QNTM SCORE
36/100
LOW CONVICTION
top 85% of the universe

As of 2026-09-10, FRPT scores 36out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. FRPT trades at $65.17, 79% above the band ceiling.

FRPT scores 36 out of 100 on QNTM's five-factor model — a low-conviction reading — at 36 the factor profile is among the weaker names in the universe. Its strongest factor is quality at 47 (middling), where earnings quality and balance-sheet strength stand out, followed by value at 45. The weakest is sentiment at 9, where sentiment signals are working against it. Among Consumer Staples stocks it sits in the lower 15% of Consumer Staples names by composite.

On valuation, FRPT is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 38. Same-sector names the model rates nearby include MO, KDP, CART.

This is a descriptive factor read on FRPT, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where FRPT sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

Momentum35
Quality47
Value45
Volume39
Sentiment9

VALUATION RANGE

QNTM’s descriptive fair-value band for FRPT runs $20.54–$36.33. Current price $65.17 sits 79% above the band ceiling. This is valuation context, not a price target.

See FRPT update live, and set an alert when its conviction changes

QNTM rescores FRPT and ~1,400 other names every session. Track it, get notified the moment it crosses a conviction tier, and see the full signal history.

Start free →

OTHER CONSUMER STAPLES NAMES

MO60KDP60CART57SJM56TGT55PM54SYY53KO52

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.